LAKE FOREST, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- Tenex Health today announced that Jay Hallinan has been appointed as its new Chief Executive Officer effective October 21, 2013. Chairman of the Board Ivan Mijatovic said of the appointment, "Jay brings the global sales and marketing experience to aggressively expand our current commercial channels with a disciplined focus on execution. This approach is critical for the expansion of current and future commercial opportunities."
Prior to accepting the CEO role at Tenex Health, Mr. Hallinan served in a senior executive sales position at Stryker Neurovascular. In that position, he was responsible for managing over $200 million in annual revenue. Additionally, Mr. Hallinan has held a number of leadership positions with 3M, Medtronic, and Boston Scientific.
Mr. Hallinan characterized the opportunity by saying, "Tenex Health is at an exciting point in its evolution as a company. The company has successfully proven the clinical and commercial viability of its innovative technology. Hundreds of U.S. physicians have successfully treated over 8,000 patients and the TX1 system is now cleared to sell in most major markets around the world."
Tenex Health's current CEO and Founder Jagi Gill, PhD will remain with the company and assume the role of Chief Scientific Officer. In this role Dr. Gill will work to leverage the technology platform and build a robust product portfolio. He will also remain on the Board of Directors. Dr. Gill said of Hallinan's appointment, "The Board has appointed a new CEO with significant experience in commercializing medical devices and I am excited to work with him to optimize our global opportunities. Our technology and organization are ready to take full advantage of those capabilities."
Mr. Hallinan is a graduate of the University of Georgia and received his M.B.A. from the McColl School of Business at Queens College.
About Tenex Health, Inc.
Tenex Health, Inc. (www.tenexhealth.com) (www.tenexhealthpatient.com) develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. The minimally invasive technique utilizes the company's proprietary TX MicroTip™ handpiece to cut and debride diseased tissue in an outpatient setting in under 20 minutes, using only a local anesthetic. Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures.